Adaptimmune
IPO
Arming cells. Against cancer. For good.
- Employees
- 201–500
- Business Model
- B2B
- Website
- adaptimmune.com
- Total Funding
- $104.0M
- Last Round
- $104.0M Venture RoundSep 2014
About
Founded in 2008, Adaptimmune develops novel T-cell receptor (TCR-T) immunotherapies for cancer treatment. The company pioneered the first FDA-approved engineered cell therapy for solid tumors (TECELRA). Headquartered in Philadelphia with UK operations, it employs approximately 300-400 people across its integrated cell therapy platform.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account